1.Alternative Name:Siglec-3；CD33 antigen (gp67); CD33 antigen; CD33 molecule; CD33; FLJ00391; gp67; myeloid cell surface antigen CD33; p67; sialic acid binding Ig-like lectin 3; Sialic acid-binding Ig-like lectin 3; Siglec3; Siglec-3; SIGLEC3gp67
2.Target:CD33
3.Source:Human CD33 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence:Asp18-His259
5.Protein structure:P20138hFC
6.Molecular Characterization:The protein has a calculated MW of 52kDa.The reducing (R) heterodimer protein migrates as 70-85 kDa due to glycosylation
7.Purity:SDS-PAGE>95%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
Note:For research use only .


11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 95%.

    

12.SEC-HPLC

Determined by SEC-HPLC, the purity of the protein is greater than 90%.

13.ELISA

When Recombinant Human CD33/hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human SIGLEC3 (Gemtuzumab) that produces 50% of the optimal binding response is approximately 30 ng/ml.